Accuracy of Self-Sampling for HPV Screening Evaluated
By LabMedica International staff writers Posted on 13 Feb 2019 |
Image: An Evalyn Brush used for patient self-sampling of the cervico-vaginal area (Photo courtesy of Rovers Medical Devices).
Molecular testing for human papillomavirus (HPV) using patient-collected cervico-vaginal samples has shown similar levels of accuracy to testing done on clinician-collected samples and could boost participation in overall HPV screening.
Detecting cancer lesions in women who periodically attend clinics can be more difficult than detecting them in underscreened women who have rarely or never been screened, or have refused to attend clinics following an invitation from a screening organization.
Scientists at the Vrije Universiteit (Amsterdam, the Netherlands) examined 7,643 women aged 29 to 61 years in a self-sampling group and 6,282 in a clinician-collected sampling group. The primary endpoints of the study were detection of cervical intraepithelial neoplasia of grade 2 and worse or grade 3 and worse (CIN2+ or CIN3+). The women were requested to collect their own cervicovaginal sample using an Evalyn Brush; or a clinician-based sampling group, in which samples were collected by a general practitioner with a Cervex-Brush also from Rovers Medical Devices BV.
All samples were tested for HPV using the clinically validated GP5+/6+ PCR enzyme immunoassay. HPV-positive women in both groups were retested with the other collection method and triaged by cytology and repeat cytology in accordance with current Dutch screening guidelines. Of the self-collecting patients, 569, or 7.4%, tested positive for HPV, while in the physician-collected group, 451, or 7.2% tested positive. The CIN2+ sensitivity and specificity of HPV testing did not differ between the two groups, while CIN3+ relative sensitivity was 0.99 with essentially equivalent specificity.
The authors concluded that HPV testing done with a clinically validated PCR-based assay had similar accuracy on self-collected and clinician-collected samples in terms of the detection of CIN2+ or CIN3+ lesions. These findings suggest that HPV self-sampling could be used as a primary. Johannes Berkhof, PhD, a professor and a co-author of the study, said, “"Self-collection has potential to become a first screening test in many different countries. It creates a high participation rate, which is difficult to achieve. We have cleared the first hurdle, but now we need to see how we can implement this kind of screening.” The study was published on January 15, 2019, in the journal Lancet Oncology.
Related Links:
Vrije Universiteit
Detecting cancer lesions in women who periodically attend clinics can be more difficult than detecting them in underscreened women who have rarely or never been screened, or have refused to attend clinics following an invitation from a screening organization.
Scientists at the Vrije Universiteit (Amsterdam, the Netherlands) examined 7,643 women aged 29 to 61 years in a self-sampling group and 6,282 in a clinician-collected sampling group. The primary endpoints of the study were detection of cervical intraepithelial neoplasia of grade 2 and worse or grade 3 and worse (CIN2+ or CIN3+). The women were requested to collect their own cervicovaginal sample using an Evalyn Brush; or a clinician-based sampling group, in which samples were collected by a general practitioner with a Cervex-Brush also from Rovers Medical Devices BV.
All samples were tested for HPV using the clinically validated GP5+/6+ PCR enzyme immunoassay. HPV-positive women in both groups were retested with the other collection method and triaged by cytology and repeat cytology in accordance with current Dutch screening guidelines. Of the self-collecting patients, 569, or 7.4%, tested positive for HPV, while in the physician-collected group, 451, or 7.2% tested positive. The CIN2+ sensitivity and specificity of HPV testing did not differ between the two groups, while CIN3+ relative sensitivity was 0.99 with essentially equivalent specificity.
The authors concluded that HPV testing done with a clinically validated PCR-based assay had similar accuracy on self-collected and clinician-collected samples in terms of the detection of CIN2+ or CIN3+ lesions. These findings suggest that HPV self-sampling could be used as a primary. Johannes Berkhof, PhD, a professor and a co-author of the study, said, “"Self-collection has potential to become a first screening test in many different countries. It creates a high participation rate, which is difficult to achieve. We have cleared the first hurdle, but now we need to see how we can implement this kind of screening.” The study was published on January 15, 2019, in the journal Lancet Oncology.
Related Links:
Vrije Universiteit
Latest Immunology News
- Diagnostic Blood Test for Cellular Rejection after Organ Transplant Could Replace Surgical Biopsies
- AI Tool Precisely Matches Cancer Drugs to Patients Using Information from Each Tumor Cell
- Genetic Testing Combined With Personalized Drug Screening On Tumor Samples to Revolutionize Cancer Treatment
- Testing Method Could Help More Patients Receive Right Cancer Treatment
- Groundbreaking Test Monitors Radiation Therapy Toxicity in Cancer Patients
- State-Of-The Art Techniques to Investigate Immune Response in Deadly Strep A Infections
- Novel Immunoassays Enable Early Diagnosis of Antiphospholipid Syndrome
- New Test Could Predict Immunotherapy Success for Broader Range Of Cancers
- Simple Blood Protein Tests Predict CAR T Outcomes for Lymphoma Patients
- Cell Sorter Chip Technology to Pave Way for Immune Profiling at POC
- Chip Monitors Cancer Cells in Blood Samples to Assess Treatment Effectiveness
- Automated Immunohematology Approaches Can Resolve Transplant Incompatibility
- AI Leverages Tumor Genetics to Predict Patient Response to Chemotherapy
- World’s First Portable, Non-Invasive WBC Monitoring Device to Eliminate Need for Blood Draw
- Predictive T-Cell Test Detects Immune Response to Viruses Even Before Antibodies Form
- Single Blood Draw to Detect Immune Cells Present Months before Flu Infection Can Predict Symptoms